Fibrous dysplasia in hospitalized patients in France: prevalence and associated manifestations from a health database
The Journal of Clinical Endocrinology & Metabolism · 2026
DOI: 10.1210/clinem/dgag209 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Lucie Levaillant und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Endocrinology and Diabetology, University Hospital of Angers, Endo-ERN Center for Rare Endocrine Conditions, Angers Cedex 9 4…. Hauptthemen laut MEDLINE: Fibrous Dysplasia, Polyostotic, Hospitalization. Die Arbeit nennt 15 Literaturangaben. Gefördert von: Société Française d'Endocrinologie et Diabétologie Pédiatrique, University Hospital of Angers, Société Française de Pédiatrie.
Abstract (Originalsprache)
Introduction
Fibrous dysplasia (FD)/McCune–Albright syndrome (MAS) is a rare mosaic disorder involving the skeleton and/or extraskeletal manifestations, particularly endocrine features. Population-based estimates of prevalence and incidence are scarce, including in France, and data on associated manifestations mainly derive from specialized centers. This study aimed to estimate the prevalence and incidence of FD/MAS in hospitalized patients in France and to evaluate the frequency of associated manifestations.
Methods
This retrospective cohort study used the French National Health Insurance Database, to identify all patients hospitalized between 2012 and 2024 with a primary or associated diagnosis of monostotic FD (MFD; ICD-10 M85.0) or polyostotic FD/MAS (PFD/MAS; ICD-10 Q78.1). Prevalence and incidence were calculated for 2024. Associated manifestations were assessed using hospitalization diagnoses and outpatient drug dispensing data.
Results
Over the 2012-2024 period, 2249 patients were hospitalized in France; 60% had PFD/MAS, 63% were female, and 26% were children. The 2024 prevalence was 5.36 per 1 000 000 inhabitants (95% CI: 4.83-5.94), and the 2024 incidence was 2.58 patients per 1 000 000 inhabitants (95% CI: 2.21-2.99). Regarding associated manifestations, 27% of patients per year received bisphosphonates, 7.4% received phosphate supplements, 3.3% aromatase inhibitors, 8% pituitary treatments, and 2.2% antithyroid agents.
Conclusion
This nationwide study provides the first estimates of the prevalence and incidence of hospitalized FD/MAS in France, although estimates based on hospitalization data likely underestimate the true frequency of monostotic FD. Treatment-based proxies offer valuable insights into associated manifestations. Improved outpatient coding and integration of clinical data are needed to better capture the full spectrum of FD/MAS at the population level.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatric Endocrinology and Diabetology, University Hospital of Angers, Endo-ERN Center for Rare Endocrine Conditions, Angers Cedex 9 49933, France.
- Univ Angers, Inserm U1083, UMR CNRS 6015, MitoVasc, CarMe Team, SFR ICAT, Angers F-49000, France.
- Reference Center for Rare Diseases of Thyroid and Hormone Receptors, University Hospital of Angers, Angers 49000, France.
- Department of Endocrinology, Diabetology and Nutrition, University Hospital of Angers, Endo-ERN Center for Rare Endocrine Conditions, Angers Cedex 9 49933, France.
- UMR 6051, EHESP, CNRS, Inserm, ARENES, RSMS U 1309, Rennes University, Rennes 35000, France.
- Methodology and Biostatistics Department, Angers University Hospital, University of Angers, Angers 49000, France.
ORCID-Profile: Lucie Levaillant, Patrice Rodien
Förderung
- Société Française d'Endocrinologie et Diabétologie Pédiatrique
- University Hospital of Angers
- Société Française de Pédiatrie
- SFR Cellular Interactions and Therapeutic Applications
- University of Angers
- Société Française d’Endocrinologie et Diabétologie Pédiatrique
Zitieren
APA
Levaillant, L., Coutant, R., Rodien, P., Levaillant, M., & Briet, C. (2026). Fibrous dysplasia in hospitalized patients in France: prevalence and associated manifestations from a health database. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag209
Vancouver
Levaillant L, Coutant R, Rodien P, Levaillant M, Briet C. Fibrous dysplasia in hospitalized patients in France: prevalence and associated manifestations from a health database. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag209
BibTeX
@article{Levaillant2026,
author = {Levaillant, Lucie and Coutant, Régis and Rodien, Patrice and Levaillant, Mathieu and Briet, Claire},
title = {Fibrous dysplasia in hospitalized patients in France: prevalence and associated manifestations from a health database},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
doi = {10.1210/clinem/dgag209}
}
EUVIMED